Edition:
India

Aravive Inc (ARAV.OQ)

ARAV.OQ on NASDAQ Stock Exchange Global Select Market

6.75USD
10:15pm IST
Change (% chg)

$0.01 (+0.15%)
Prev Close
$6.74
Open
$6.79
Day's High
$6.79
Day's Low
$6.75
Volume
979
Avg. Vol
6,855
52-wk High
$9.72
52-wk Low
$3.07

Latest Key Developments (Source: Significant Developments)

Aravive Presents Positive Data From Initial 12 Patients In Phase 1B Portion Of Its Phase 1B/2 Ovarian Cancer Study Of Avb-500 In Late Breaking Oral Presentation At European Society For Medical O
Friday, 27 Sep 2019 

Sept 27 (Reuters) - Aravive Inc ::ARAVIVE PRESENTS POSITIVE DATA FROM INITIAL 12 PATIENTS IN PHASE 1B PORTION OF ITS PHASE 1B/2 OVARIAN CANCER STUDY OF AVB-500 IN LATE BREAKING ORAL PRESENTATION AT EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY CONGRESS IN BARCELONA.ARAVIVE INC - PLANS TO REPORT DETAILED ANALYSIS ONCE DATA FROM INITIAL 30 PATIENTS ON CURRENT 10 MG/KG DOSE MATURE TOWARD END OF YEAR.ARAVIVE INC - INTENDS TO EXPLORE POTENTIAL FOR AN ACCELERATED REGULATORY PATHWAY FOR AVB-500 WITH FDA.ARAVIVE INC - AVB-500 WAS WELL TOLERATED WITH NO DOSE LIMITING TOXICITIES (DLT).ARAVIVE INC - AVB-500 WAS WELL TOLERATED WITH NO DOSE LIMITING TOXICITIES.ARAVIVE INC - PLANS TO INCORPORATE EXPOSURE-RESPONSE INFORMATION INTO THEIR PLANNED STUDIES IN CLEAR CELL RENAL CANCER & RENAL FIBROSIS TRIALS.  Full Article

Aravive Says Q2 Revenue $3.1 Million
Thursday, 8 Aug 2019 

Aug 7 (Reuters) - Aravive Inc ::ARAVIVE REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES RECENT CORPORATE UPDATES.Q2 REVENUE $3.1 MILLION.AT JUNE 30, 2019, CASH AND CASH EQUIVALENTS WERE $48.4 MILLION.QTRLY NET LOSS PER SHARE $0.27.  Full Article

Aravive Q1 Loss Per Share $0.42
Thursday, 9 May 2019 

May 8 (Reuters) - Aravive Inc ::ARAVIVE REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES RECENT CORPORATE UPDATES.Q1 LOSS PER SHARE $0.42.CASH AND CASH EQUIVALENTS WERE $55.6 MILLION AS OF MARCH 31, 2019.  Full Article

Aravive Says Co May Offer Shares Of Common Stock Having Aggregate Offering Price Of Up To $20.25 Million
Tuesday, 26 Mar 2019 

March 26 (Reuters) - Aravive Inc ::ARAVIVE-MAY OFFER/ SELL SHARES OF COMMON STOCK HAVING AGGREGATE OFFERING PRICE OF UP TO $20.25 MILLION FROM TIME TO TIME THROUGH PIPER JAFFRAY-SEC FILING.  Full Article

Aravive Reports Fourth Quarter And Full Year 2018 Financial Results
Friday, 8 Mar 2019 

March 7 (Reuters) - Aravive Inc ::ARAVIVE REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES RECENT CORPORATE UPDATES.Q4 LOSS PER SHARE $4.82.CASH AND CASH EQUIVALENTS WERE $57.0 MILLION AS OF DECEMBER 31, 2018.EXPECTS CURRENT CASH AND CASH EQUIVALENTS WILL ENABLE COMPANY TO FUND ITS OPERATING PLANS INTO END OF 2020.QTRLY TOTAL REVENUE $1.4 MILLION VERSUS $40 MILLION.  Full Article

Aravive Presents Detailed Results Of Phase 1 Clinical Trial Of AVB-S6-500 At The 2018 EORTC-NCI-AACR Symposium
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Aravive Inc ::ARAVIVE PRESENTS DETAILED RESULTS OF PHASE 1 CLINICAL TRIAL OF AVB-S6-500 AT THE 2018 EORTC-NCI-AACR SYMPOSIUM.ARAVIVE INC - PHASE 1 CLINICAL TRIAL IN HEALTHY VOLUNTEERS DEMONSTRATED THAT AVB-S6-500 WAS WELL TOLERATED WITH AN ACCEPTABLE SAFETY PROFILE..ARAVIVE INC - THERE WERE NO SERIOUS ADVERSE EVENTS (AES) AND AVB-S6-500 WAS WELL TOLERATED ACROSS ALL DOSES.  Full Article

Versartis Q1 Loss Per Share $0.25
Wednesday, 9 May 2018 

May 8 (Reuters) - Versartis Inc ::VERSARTIS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.25.CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS WERE $74.7 MILLION AS OF MARCH 31, 2018.  Full Article

Versartis reports Q3 loss $1.40/shr
Friday, 27 Oct 2017 

Oct 26 (Reuters) - Versartis Inc :Versartis reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $1.40.Q3 earnings per share view $-0.71 -- Thomson Reuters I/B/E/S.  Full Article